Patient Insights: EczemaEllen Scheib has had eczema for over twenty years, and though drugs have helped her manage the condition Share XPatient Insights: Eczemahttps://pharmaphorum.com/views-analysis-patients/patient-insights-eczema/
Incyte gets much-needed boost as eczema cream trial hits targetUS biotech Incyte has announced positive topline results from a phase 3 trial of its ruxolitinib eczema cream Share XIncyte gets much-needed boost as eczema cream trial hits targethttps://pharmaphorum.com/news/incyte-gets-much-needed-boost-as-eczema-cream-trial-hits-target/
Sanofi’s Dupixent funded in Wales and Scotland for adolescents with eczemaSanofi’s Dupixent (dupilumab) has been cleared for NHS funding in Wales and Scotland in adolescents with severe eczema, Share XSanofi’s Dupixent funded in Wales and Scotland for adolescents with eczemahttps://pharmaphorum.com/news/sanofis-dupixent-funded-in-wales-and-scotland-for-adolescents-with-eczema/
Novartis’ $100m bet on eczema drug fails as MOR106 development endsGalapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in Share XNovartis’ $100m bet on eczema drug fails as MOR106 development endshttps://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/
Sanofi’s eczema drug gets EU approval to treat adolescentsThe European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron’s eczema drug Dupixent (dupilumab) to Share XSanofi’s eczema drug gets EU approval to treat adolescentshttps://pharmaphorum.com/news/sanofi-eczema-drug-gets-eu-approval-adolescents/
Almirall gets in on the eczema actionSanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall Share XAlmirall gets in on the eczema actionhttps://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/
Patient Insights: Severe psoriasis & eczemaHoward Chang has lived with severe psoriasis and atopic dermatitis for almost 40 years since childhood. Now a Share XPatient Insights: Severe psoriasis & eczemahttps://pharmaphorum.com/views-analysis-patients/patient-insights-severe-psoriasis-eczema/
FDA approves Sanofi/Regeneron’s Dupixent in asthmaThe US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the Share XFDA approves Sanofi/Regeneron’s Dupixent in asthmahttps://pharmaphorum.com/news/fda-approves-sanofi-regenerons-dupixent-in-asthma/
Sanofi showcases eczema data ahead of EU decisionDupixent predicted to be blockbuster for Sanofi Share XSanofi showcases eczema data ahead of EU decisionhttps://pharmaphorum.com/news/dupixent-data-sanofi-ahead-eu-decision/
